NCT06406556View on ClinicalTrials.gov

Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Extranodal NK/T-cell Lymphoma
Interventions
COMBINATION_PRODUCT

Pegaspargase combined with concurrent radiotherapy.

Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks). 4 courses of pegaspargase were performed after CCRT.

Trial Locations (1)

510060

RECRUITING

HuaWang, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER